Overview 

This guide section explains how FDA-approved CAR T-cell therapies for myeloma work and discusses their common side effects. 

The current brands include: 

• Ciltacabtagene autoleucel (cilta-cel, Carvykti, Johnson & Johnson/Legend Biotech)
• Idecabtagene vicleucel (ide-cel, Abecma, Bristol-Myers Squibb/2seventy bio) 

Please note that these treatments have not yet been directly compared to each other in a head-to-head clinical trial. For more information on comparing the therapies in a retrospective analysis, read our article: Which CAR-T is the Best for You? Comparing Cilta-cel and Ide-cel. 

The information in this guide should not take the place of having conversations with your myeloma specialist about making treatment decisions. If you have questions about your myeloma treatment, you can also contact our patient navigators here.